Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-421286 in advanced solid tumors
NCT05315180Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BPI-421286 in solid tumor (advanced stage) (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Safety and Tolerability of BPI-421286 at 20 months and Recommended Phase 2 Dose at 20 months. Status: unknown.
02
Drugs
BPI-421286
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05315180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315180.